Guggenheim Lifts Savara (SVRA) Price Target on Pulmonary Alveolar Proteinosis Opportunity

Savara Inc. (NASDAQ:SVRA) is one of the best healthcare penny stocks to buy now. On September 9, Guggenheim raised its price target of the stock to $11 from $8 while reiterating a Buy rating. The price target hike follows an impressive 16% stock rally year to date. Guggenheim Lifts Savara (SVRA) Price Target on Pulmonary Alveolar Proteinosis Opportunity The research firm raised its price target, buoyed by positive developments that affirm long-term prospects. For starters, the company has achieved alignm ...